Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens

Vaccine

Volumn 29, Issue 47, 2011, Pages 8487-8489

  Feller, Andrea J ^a   McKenzie, Robin ^a,b   Taylor, David N ^a,e   Woods, Colleen C ^a,f   Grahek, Shannon L ^a,g   Islam, Dilara ^c   Venkatesan, Malabi M ^d   Hale, Thomas L ^d   Bourgeois, August L ^a,f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e VaxInnate Inc   (United States)

^f PATH   (United States)

^g SABIN VACCINE INSTITUTE   (United States)

Author keywords

ALS; ELISPOT; Mucosal immune response; Shigella

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; RIFAXIMIN; SHIGELLA VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LOGISTIC REGRESSION ANALYSIS; MUCOSAL IMMUNITY; PRIORITY JOURNAL; SHIGELLA; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLOSIS; STATISTICAL MODEL; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNITY, MUCOSAL; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYMPHOCYTES; SHIGELLA;

EID: 82455172069     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.030     Document Type: Article

References (16)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77(8):651-666.
2. Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol 2007, 45(February (2)):678-679.
3. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006, 3(September (9)):e353.
4. WHO Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 2006, 81(February (6)):51-58.
5. Qadri F., Ryan E.T., Faruque A.S., Ahmed F., Khan A.I., Islam M.M., et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003, 71(August (8)):4808-4814.
6. Carpenter C.M., Hall E.R., Randall R., McKenzie R., Cassels F., Diaz N., et al. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine 2006, 24(May (18)):3709-3718.
7. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990, 8(August (4)):321-326.
8. Chang H.S., Sack D.A. Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes. Clin Diagn Lab Immunol 2001, 8(May (3)):482-488.
9. UNICEF. Child survival fact sheet: water and sanitation. Available from: [cited 15.01.08]. http://www.unicef.org/media/media_21423.html.
10. Kirkpatrick B.D., Bentley M.D., Thern A.M., Larsson C.J., Ventrone C., Sreenivasan M.V., et al. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin Diagn Lab Immunol 2005, 12(September (9)):1127-1129.
11. Taylor D.N., McKenzie R., Durbin A., Carpenter C., Atzinger C.B., Haake R., et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006, 42(May (9)):1283-1288.
12. DiPetrillo M.D., Tibbetts T., Kleanthous H., Killeen K.P., Hohmann E.L. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999, 18(October (5-6)):449-459.
13. McKenzie R., Bourgeois A.L., Engstrom F., Hall E., Chang H.S., Gomes J.G., et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun 2006, 74(February (2)):994-1000.
14. Turner A.K., Terry T.D., Sack D.A., Londono-Arcila P., Darsley M.J. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun 2001, 69(August (8)):4969-4979.
15. McKenzie R., Venkatesan M.M., Wolf M.K., Islam D., Grahek S., Jones A.M., et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate, in human volunteers. Vaccine 2008, 26:3291-3296.
16. WHO Enterotoxigenic Escherichia coli: advances in technical and laboratory aspects of research and development of vaccines. Wkly Epidemiol Rec 2008, 83(10):92-95.